Lv7
3270 积分 2021-10-09 加入
HER family receptor and ligand status in thymic carcinoma
2天前
已完结
Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase Ib study
2天前
已完结
Longitudinal PET RANO 1.0 and RANO 2.0 response assessment in vorasidenib-treated IDH -mutant gliomas: the VORAFET study
4天前
已完结
EP13.01: Neoadjuvant Adebrelimab Combined With Chemotherapy Followed by Surgical Resection for Limited-Stage Small-Cell Lung Cancer: A Cohort Study
7天前
已关闭
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
8天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
16天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
16天前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
17天前
已完结
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA
21天前
已完结
Clinical outcomes for neoadjuvant immunochemotherapy or chemotherapy versus concurrent chemoradiotherapy in limited‐stage small‐cell lung cancer: A retrospective, multi‐center, real‐world study
25天前
已完结